In this episode of Results are In by Quest Diagnostics, Dr. Jack Kain joins Jason Suomala to explain the threat of novel psychoactive substances and how Quest's updated testing panel helps providers identify what's being used and treat patients with more confidence.

They break down what providers need to know about NPS classes like designer benzodiazepines, fentanyl analogs, synthetic cannabinoids, and more. With real-world case studies and clinical insights, the discussion highlights why traditional drug testing often misses these compounds—and how Quest’s updated NPS panel helps providers detect risk and guide treatment with greater accuracy.

The episode also explores how the evolving drug landscape, fueled by counterfeit pills and illicit drug mixing, is increasing overdose risks across the country. Whether you're a healthcare professional, toxicologist, or public health advocate, this conversation will help you better understand what’s really showing up in patients’ systems and what to do about it.

Follow Us
Twitter @QuestDX
Facebook @QuestDiagnostics
Instagram @QuestDiagnostics

LinkedIn @QuestDiagnostics

Presented by Quest Diagnostics

www.questdiagnostics.com

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.